Secondary analysis
Combination Moderate-Intensity Statin and Ezetimibe Therapy for Elderly Patients With Atherosclerosis
- Secondary analysis of the RACING randomised trial
- post hoc analysis
- stratified by age (≥75 years and <75 years)
Authors' conclusion
Moderate-intensity statin with ezetimibe combination therapy showed similar cardiovascular benefits to those of high-intensity statin monotherapy with lower intolerance-related drug discontinuation or dose reduction in elderly patients with ASCVD having a higher risk of intolerance, nonadherence, and discontinuation with high-intensity statin therapy.
Study context
- Population
- Patients with atherosclerotic cardiovascular disease (ASCVD), stratified by age (≥75 years and <75 years)574 (15.2%) aged ≥75 years
- Participants
- 3,780 patients
- Comparison
- Moderate-intensity statin + ezetimibe vs high-intensity statin monotherapy, by age
- Primary endpoint
- Composite of:
- CV death
- Major CV events
- Nonfatal stroke
- Follow-up
- 3 years
Primary result
As reported in the abstract
Primary endpoint by age subgroup
Moderate-intensity statin with ezetimibe vs High-intensity statin monotherapyHazard ratio (95% CI)P value
aged ≥75 years: 10.6% vs 12.3%
0.87(0.54–1.42)
P = 0.581aged <75 years: 8.8% vs 9.4%
0.94(0.74–1.18)
P = 0.570Safety
Intolerance-related drug discontinuation or dose reduction, by age subgroup · aged ≥75 years
P = 0.010
Intolerance-related drug discontinuation or dose reduction, by age subgroup · aged <75 years
P < 0.001
- Intolerance-related drug discontinuation or dose reduction, by age subgroup: P for interaction = 0.159
Original publication
Combination Moderate-Intensity Statin and Ezetimibe Therapy for Elderly Patients With Atherosclerosis. J Am Coll Cardiol. Published 11 April 2023. doi:10.1016/j.jacc.2023.02.007
Summarised from the published abstract; every number is checked against it